Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Hold at Leerink Partnrs

Compass Therapeutics (NASDAQ:CMPX) was downgraded by investment analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating in a research report issued on Friday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research note on Monday, September 16th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $5.00 to $4.00 in a research report on Friday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $1.38 on Friday. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34. The firm has a market capitalization of $189.87 million, a PE ratio of -3.73 and a beta of 0.92. The company’s 50 day simple moving average is $1.75 and its 200 day simple moving average is $1.42.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. Sell-side analysts anticipate that Compass Therapeutics will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the 3rd quarter worth about $25,000. Intech Investment Management LLC bought a new stake in Compass Therapeutics in the third quarter worth approximately $30,000. XTX Topco Ltd bought a new position in shares of Compass Therapeutics during the 3rd quarter valued at $37,000. SG Americas Securities LLC lifted its stake in shares of Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after purchasing an additional 5,515 shares during the last quarter. Finally, Bleakley Financial Group LLC bought a new stake in Compass Therapeutics in the first quarter worth $80,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.